G-BA Nutzenbewertung — Veltarix Module 4 Lessons Learned
Prepared by HTA Lead, DACH region. Distribution: HTA leads (NICE, HAS, CADTH, JCA), HEOR Director, VP Commercial, Clinical Development. Confidential — for internal learning.
Background
This document captures the lessons learned from the November 2024 G-BA Nutzenbewertung outcome for Veltarix (zenvalimab) in 2L metastatic NSCLC. The benefit assessment was downgraded to 'non-quantifiable' (Anhaltspunkt) — the second-lowest tier in the AMNOG framework — primarily due to a comparator-selection misalignment between our submission and the G-BA-defined zweckmäßige Vergleichstherapie (ZVT).
What went wrong
We submitted Module 4 with docetaxel as the appropriate comparator therapy, based on the assumption that docetaxel was the prevailing standard of care in 2L NSCLC patients who had progressed after immunotherapy in 1L. This assumption was wrong. G-BA's ZVT determination, communicated in the scoping consultation, was pembrolizumab monotherapy as 2L re-treatment, not docetaxel.
We did not align with G-BA's ZVT determination in the scoping consultation. The scoping consultation was held September 2024; the G-BA position on ZVT was clearly stated in writing in the scoping minutes. Our internal review of the scoping minutes flagged the disagreement but recommended proceeding with our chosen comparator (docetaxel) on the rationale that the manufacturer model would defend it. This was a strategic error.
The IQWiG (Institute for Quality and Efficiency in Health Care) assessment, published October 2024, found that the comparator selection rendered the patient-relevant endpoints analysis non-quantifiable because the comparison was not against the standard treatment that G-BA had specified. IQWiG explicitly noted: 'The ZVT specified by G-BA is pembrolizumab monotherapy. The presented data compare zenvalimab against docetaxel and therefore cannot inform a benefit assessment relative to standard care.'
Decision outcome
G-BA's resolution (Beschluss) of November 4, 2024 categorized Veltarix as 'Anhaltspunkt für einen geringen Zusatznutzen nicht belegt' — 'evidence for a minor additional benefit not demonstrated'. This is one tier above the lowest possible designation (no additional benefit demonstrated). The Beschluss has significant downstream pricing implications: AMNOG pricing negotiation with the GKV-Spitzenverband will likely result in a price reduction of 30-45% from the European reference price.
Root causes
Root cause 1 — Inadequate weight given to G-BA ZVT determination during dossier preparation. The team prioritized internal modeling preferences (docetaxel comparison was a cleaner direct comparison) over G-BA's documented preference. The cost of the misalignment was the entire submission outcome.
Root cause 2 — Insufficient pre-submission engagement with G-BA on ZVT alternatives. We had the opportunity to formally challenge or seek clarification on the ZVT determination during scoping; we did not.
Root cause 3 — Internal governance allowed proceeding with a known disagreement. The internal review correctly flagged the ZVT misalignment but the recommendation to proceed anyway was approved without escalation. The governance pathway for known regulatory disagreements was not adequately defined.
Recommended remediation for 2026 resubmission
Resubmit Module 4 with pembrolizumab as the ZVT-aligned comparator, with the ITC vs pembrolizumab as the primary patient-relevant endpoints comparison. This work is in progress as part of the global evidence dossier (asset CL-007 in the Evidence Dossier Index).
Confirm the ZVT with G-BA in a formal pre-submission consultation at least 4 months before submission. The consultation request should be filed by July 2026 for a Q4 2026 resubmission window.
Establish governance for known regulatory disagreements: any disagreement with G-BA ZVT, NICE EAG positioning, HAS Doctrine guidance, or CADTH common drug review framework must be escalated to the HEOR Director plus the VP Commercial for explicit decision-making.
Engage IQWiG informally before submission to test the methodology and reduce surprise during their formal review.
Lessons applicable to other HTA bodies
NICE EAG: pre-engagement at tech engagement meetings is the analog of the G-BA pre-submission consultation. The NICE STA process explicitly invites manufacturer-EAG engagement; use it.
HAS Commission de la Transparence: HAS publishes its Doctrine annually and updates technical positions through circulars. Internal monitoring of these publications should be quarterly, not annual.
CADTH: comparator selection is governed by clinical context per CADTH Methods Guidance. Pre-submission engagement via the Pre-submission Information Requirements Form is mandatory; treat it as a binding scoping document.
JCA: PICO scope is consolidated from member states during the 130-day scoping phase. There is no opportunity for the manufacturer to formally challenge the consolidated PICO scope after it is fixed. The lesson: invest in member-state engagement during scoping.
Status of remediation
2026 resubmission ZVT alignment: ITC vs pembrolizumab complete (CL-007 in dossier). Module 4 redrafted, internal review in progress.
Pre-submission consultation: request filed June 12, 2026 for an August 8 consultation date. Confirmed by G-BA.
Governance: regulatory disagreement escalation pathway formalized in Q1 2026. Now mandatory for all HTA submissions globally.
IQWiG engagement: informal methodology preview scheduled August 22, 2026 (pre-submission, post-consultation).
Cross-references
Evidence Dossier Index (1I8…), HTA Evidence Gap Report Q2 2026 (1J4…), NICE STA Submission Plan (1H3…).